$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000119312514401322 Filed on November 06, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q4
Revenue	$3.328B	$3.252B	$3.063B
YoY Change	8.64%	8.41%	23.62%
Cost Of Revenue	$2.367B	$2.327B	$2.128B
YoY Change	11.22%	11.03%	24.61%
Gross Profit	$961.6M	$925.3M	$935.4M
YoY Change	2.8%	2.32%	21.42%
Gross Profit Margin	28.89%	28.45%	30.54%
Selling, General & Admin	$360.8M	$326.8M	$320.0M
YoY Change	12.75%	6.59%	16.53%
% of Gross Profit	37.52%	35.32%	34.21%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$153.6M	$149.2M	$138.7M
YoY Change	10.74%	12.38%	26.67%
% of Gross Profit	15.97%	16.12%	14.83%
Operating Expenses	$513.9M	$476.0M	$459.5M
YoY Change	11.84%	8.33%	19.69%
Operating Profit	$452.1M	$437.5M	$484.2M
YoY Change	-6.63%	16.03%	24.77%
Interest Expense	-$93.40M	-$94.70M	-$99.30M
YoY Change	-5.94%	-4.54%	0.51%
% of Operating Profit	-20.66%	-21.64%	-20.51%
Other Income/Expense, Net	$200.0K	-$1.246M	$3.500M
YoY Change	-94.29%	-158.97%	250.0%
Pretax Income	$354.4M	$336.4M	$380.0M
YoY Change	-6.75%	24.24%	34.68%
Income Tax	$104.0M	$116.6M	$135.7M
% Of Pretax Income	29.35%	34.67%	35.71%
Net Earnings	$208.0M	$184.1M	$212.3M
YoY Change	-2.01%	34.76%	36.22%
Net Earnings / Revenue	6.25%	5.66%	6.93%
Basic Earnings Per Share	$0.98	$0.87	$1.01
Diluted Earnings Per Share	$0.96	$0.85	$0.99
COMMON SHARES
Basic Shares Outstanding	214.9M shares	212.6M shares	212.7M shares
Diluted Shares Outstanding		217.2M shares

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.101B	$1.669B	$971.3M
YoY Change	13.36%	70.83%	79.53%
Cash & Equivalents	$736.9M	$1.527B	$946.2M
Short-Term Investments	$364.1M	$142.0M	$25.02M
Other Short-Term Assets	$186.8M	$172.3M	$176.4M
YoY Change	5.91%	9.76%	-12.48%
Inventory	$136.1M	$114.7M	$88.81M
Prepaid Expenses	$102.5M		$93.88M
Receivables	$1.526B	$1.469B	$1.485B
Other Receivables	$400.9M	$346.0M	$349.1M
Total Short-Term Assets	$3.636B	$4.178B	$3.472B
YoY Change	4.72%	23.57%	20.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.469B	$2.359B	$2.189B
YoY Change	12.77%	15.18%	16.93%
Goodwill	$9.415B	$9.345B	$9.213B
YoY Change	2.2%	2.19%	2.91%
Intangibles	$1.865B	$1.998B	$2.024B
YoY Change	-7.88%	-3.0%	-4.87%
Long-Term Investments	$155.0M	$154.0M	$120.0M
YoY Change	29.17%	35.09%	27.66%
Other Assets	$77.00M	$67.33M	$79.60M
YoY Change	-3.26%	-15.66%	-0.32%
Total Long-Term Assets	$13.98B	$13.92B	$13.63B
YoY Change	2.6%	3.55%	3.8%
TOTAL ASSETS
Total Short-Term Assets	$3.636B	$4.178B	$3.472B
Total Long-Term Assets	$13.98B	$13.92B	$13.63B
Total Assets	$17.62B	$18.10B	$17.10B
YoY Change	3.03%	7.57%	6.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$445.5M	$442.2M	$435.5M
YoY Change	2.29%	23.38%	5.15%
Accrued Expenses	$824.0M	$762.0M	$772.0M
YoY Change	6.74%	11.24%	36.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$120.0M	$121.5M	$274.7M
YoY Change	-56.32%	-53.26%	20.48%
Total Short-Term Liabilities	$2.089B	$2.598B	$2.462B
YoY Change	-15.17%	5.89%	22.1%
LONG-TERM LIABILITIES
Long-Term Debt	$8.299B	$8.381B	$8.141B
YoY Change	1.94%	2.44%	-2.23%
Other Long-Term Liabilities	$389.8M	$368.5M	$380.3M
YoY Change	2.49%	4.17%	-14.29%
Total Long-Term Liabilities	$389.8M	$368.5M	$380.3M
YoY Change	2.49%	4.17%	-14.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.089B	$2.598B	$2.462B
Total Long-Term Liabilities	$389.8M	$368.5M	$380.3M
Total Liabilities	$11.43B	$12.19B	$11.80B
YoY Change	-3.13%	3.59%	2.42%
SHAREHOLDERS EQUITY
Retained Earnings	$4.087B	$3.879B	$3.364B
YoY Change	21.5%	23.08%	-9.86%
Common Stock	$1.108B	$215.0K	$213.0K
YoY Change	520288.26%	0.94%	-21.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares			0.000 shares
Shareholders Equity	$5.171B	$4.975B	$4.432B
YoY Change
Total Liabilities & Shareholders Equity	$17.62B	$18.10B	$17.10B
YoY Change	3.03%	7.57%	6.77%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q4
OPERATING ACTIVITIES
Net Income	$208.0M	$184.1M	$212.3M
YoY Change	-2.01%	34.76%	36.22%
Depreciation, Depletion And Amortization	$153.6M	$149.2M	$138.7M
YoY Change	10.74%	12.38%	26.67%
Cash From Operating Activities	-$70.00M	$847.9M	$354.1M
YoY Change	-119.77%	15.64%	76.87%
INVESTING ACTIVITIES
Capital Expenditures	-$197.8M	$164.9M	-$218.1M
YoY Change	-9.31%	-216.88%	27.39%
Acquisitions
YoY Change
Other Investing Activities	-$248.7M	-$223.4M	-$81.70M
YoY Change	204.41%	153.58%	-97.89%
Cash From Investing Activities	-$446.5M	-$388.3M	-$299.8M
YoY Change	48.93%	69.42%	-92.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-46.00M	-355.6M	-78.80M
YoY Change	-41.62%	136.28%	-101.97%
NET CHANGE
Cash From Operating Activities	-70.00M	847.9M	354.1M
Cash From Investing Activities	-446.5M	-388.3M	-299.8M
Cash From Financing Activities	-46.00M	-355.6M	-78.80M
Net Change In Cash	-562.5M	104.0M	-24.50M
YoY Change	2195.92%	-70.58%	-116.08%
FREE CASH FLOW
Cash From Operating Activities	-$70.00M	$847.9M	$354.1M
Capital Expenditures	-$197.8M	$164.9M	-$218.1M
Free Cash Flow	$127.8M	$683.0M	$572.2M
YoY Change	-77.67%	-21.88%	54.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5151475000
CY2014Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	758743000
CY2014Q3	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	1997894000
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	970694000
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	214878274	shares
CY2014Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	503198000
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	214900000	shares
CY2014Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	5500000000
CY2014Q2	dva	Line Of Credit Facility Additional Borrowing Capacity LineOfCreditFacilityAdditionalBorrowingCapacity	1500000000
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	214878274	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q3	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0446	pure
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	312363000
CY2014Q3	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	27427000
CY2014Q3	us-gaap	Senior Notes SeniorNotes	3775000000
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	116633000
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2597631000
CY2014Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	194689000
CY2014Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	5594000
CY2014Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	48732000
CY2014Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	33207000
CY2014Q3	us-gaap	Other Commitment OtherCommitment	2000000
CY2014Q3	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8380903000
CY2014Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	96000000
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	215000
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11624000
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	442183000
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3879083000
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	154782000
CY2014Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	121530000
CY2014Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	844189000
CY2014Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8519286000
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	4975042000
CY2014Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	368475000
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	142834000
CY2014Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	121530000
CY2014Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	414000000
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18101416000
CY2014Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	577124000
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1107368000
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	35170000
CY2014Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	33207000
CY2014Q3	us-gaap	Minority Interest MinorityInterest	176433000
CY2014Q3	us-gaap	Liabilities Liabilities	12191198000
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	761912000
CY2014Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	10802000
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	113185000
CY2014Q3	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	1000000000
CY2014Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	235192000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1527035000
CY2014Q3	us-gaap	Goodwill Goodwill	9344641000
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2359203000
CY2014Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	24837000
CY2014Q3	us-gaap	Other Receivables OtherReceivables	346712000
CY2014Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	16853000
CY2014Q3	us-gaap	Long Term Investments LongTermInvestments	87307000
CY2014Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	572026000
CY2014Q3	us-gaap	Assets Assets	18101416000
CY2014Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	407071000
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	87729000
CY2014Q3	us-gaap	Inventory Net InventoryNet	114677000
CY2014Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	66728000
CY2014Q3	us-gaap	Short Term Investments ShortTermInvestments	142122000
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1468563000
CY2014Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1997772000
CY2014Q3	us-gaap	Other Assets Current OtherAssetsCurrent	172255000
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	67330000
CY2014Q3	us-gaap	Assets Current AssetsCurrent	4178435000
CY2014Q3	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	124105000
CY2014Q3	us-gaap	Investments Investments	166959000
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4605541000
CY2014Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	221365000
CY2014Q3	dva	Mutual Fund Investments At Fair Value MutualFundInvestmentsAtFairValue	26237000
CY2014Q3	dva	Long Term Debt Maturities Repayments Of Principal In Year Seven And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSevenAndThereafter	7228379000
CY2014Q3	dva	Settlement Agreement Amount SettlementAgreementAmount	11500000
CY2014Q3	dva	Medical Expense Payable MedicalExpensePayable	306076000
CY2014Q3	dva	Percentage Of Outstanding Patient Accounts Receivables PercentageOfOutstandingPatientAccountsReceivables	1.00	pure
CY2014Q3	dva	Line Of Credit Weighted Average Interest Rate LineOfCreditWeightedAverageInterestRate	0.0343	pure
CY2014Q3	dva	Long Term Debt And Capital Lease Obligations Noncurrent LongTermDebtAndCapitalLeaseObligationsNoncurrent	8380903000
CY2014Q3	dva	Carrying Amount Of Longterm Debt Net Of Unamortized Discount Or Premium Current And Noncurrent CarryingAmountOfLongtermDebtNetOfUnamortizedDiscountOrPremiumCurrentAndNoncurrent	8502433000
CY2014Q3	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	41163000
CY2014Q3	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	70847000
CY2014Q3	dva	Long Term Debt Maturities Repayments Of Principal In Year Six LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix	728303000
CY2014Q3	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9593567000
CY2014Q3	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	140722000
CY2014Q3	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1182837000
CY2014Q3	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet	147760000
CY2014Q3	dva	Additional Other Potential Commitments AdditionalOtherPotentialCommitments	1000000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	533748000
CY2012Q4	us-gaap	Goodwill Goodwill	8952750000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	213163248	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	213163248	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	697300000
CY2013Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	1778259000
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	464422000
CY2013Q4	us-gaap	Senior Notes SeniorNotes	2800000000
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2462049000
CY2013Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	152751000
CY2013Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	5096000
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8141231000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	213000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2645000
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	435465000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3363989000
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	274697000
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	812419000
CY2013Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8433603000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	4432479000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	380337000
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	274697000
CY2013Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	397000000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17098877000
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	483773000
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1070922000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	60538000
CY2013Q4	us-gaap	Minority Interest MinorityInterest	173062000
CY2013Q4	us-gaap	Liabilities Liabilities	11796036000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	603013000
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	10742000
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	237143000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	946249000
CY2013Q4	us-gaap	Goodwill Goodwill	9212974000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2189411000
CY2013Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	18221000
CY2013Q4	us-gaap	Other Receivables OtherReceivables	349090000
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	17675000
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	79557000
CY2013Q4	us-gaap	Assets Assets	17098877000
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	409441000
CY2013Q4	us-gaap	Inventory Net InventoryNet	88805000
CY2013Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	40686000
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	6801000
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1485163000
CY2013Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10315000
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2024373000
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	176414000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79598000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	3472278000
CY2013Q4	us-gaap	Investments Investments	25022000
CY2013Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	199841000
CY2013Q4	dva	Mutual Fund Investments At Fair Value MutualFundInvestmentsAtFairValue	19421000
CY2013Q4	dva	Medical Expense Payable MedicalExpensePayable	287452000
CY2013Q4	dva	Long Term Debt And Capital Lease Obligations Noncurrent LongTermDebtAndCapitalLeaseObligationsNoncurrent	8141231000
CY2013Q4	dva	Carrying Amount Of Longterm Debt Net Of Unamortized Discount Or Premium Current And Noncurrent CarryingAmountOfLongtermDebtNetOfUnamortizedDiscountOrPremiumCurrentAndNoncurrent	8415928000
CY2013Q4	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	28058000
CY2013Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	67352000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	407919000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	719000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	399527000
CY2013Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9333987000
CY2013Q4	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	5601000
CY2013Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1040866000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.96
	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-1340000
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2713000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1419154000
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.90
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	214631587	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.01
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.95
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.06
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3871000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	209725439	shares
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	6630000
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1034000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1206000
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	6155223000
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8700841000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	399527000
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	99736000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	11083000
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	421168000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17861000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	13249000
	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	2219953000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	31722000
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	17466000
	us-gaap	Profit Loss ProfitLoss	512928000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5494000
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	5938498000
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	234802000
	us-gaap	Operating Income Loss OperatingIncomeLoss	1065955000
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	542390000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	432251000
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	50325455000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	13236000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	744958000
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-139000
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	474000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1337000
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	1583000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	421168000
	us-gaap	Net Income Loss NetIncomeLoss	421168000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-20856000
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	13375000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1367000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	26239000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	499692000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	524011000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-52085000
	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	40870000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	389263000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-899000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	114877000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	91503000
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	1376000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-56977000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	31722000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-15212000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	51757000
	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	397000000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3636000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	436946000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	245266000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-577086000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-9433000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	389263000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-19922000
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	322334000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-404223000
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	6083000
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	62282000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12432000
	us-gaap	Costs And Expenses CostsAndExpenses	7634886000
	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	216725000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	155000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	857658000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-71581000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	91760000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1091000
	us-gaap	Share Based Compensation ShareBasedCompensation	47095000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	906226000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	91760000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	94000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	49941883000
	dva	Debt Expense DebtExpense	322334000
	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	5000	shares
	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	407919000
	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	211914000	shares
	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	407919000
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	41055000
	dva	Income Loss From Discontinued Operations Per Basic Share IncomeLossFromDiscontinuedOperationsPerBasicShare	0.06
	dva	Patient Care Costs PatientCareCosts	6070545000
	dva	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest	30041000
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	35757000
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	5039000
	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	389387000
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-384301000
	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	211000
	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	-54203000
	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-1074000
	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	58204000
	dva	Payments To Acquire Intangible Assets And Equity Method Investments PaymentsToAcquireIntangibleAssetsAndEquityMethodInvestments	53000
	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	322334000
	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	419828000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.38
	us-gaap	Significant Supply Commitment Description SignificantSupplyCommitmentDescription	Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years.
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	DAVITA HEALTHCARE PARTNERS INC.
	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
	dei	Trading Symbol TradingSymbol	DVA
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>18. New accounting standards</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, <i>Revenue from Contracts with Customers</i>, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In April 2014, the FASB issued ASU No. 2014-08<i>, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</i>. The amendments in the ASU change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of an organization that does not qualify for discontinued operations reporting. This disclosure will provide users with information about the ongoing trends in a reporting organization’s results from continuing operations. The amendments in this ASU enhance convergence between U.S. GAAP and International Financial Reporting Standards (IFRS). Part of the new definition of discontinued operation is based on elements of the definition of discontinued operations in IFRS 5, <i>Non-Current Assets Held for Sale and Discontinued Operations</i>. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s condensed consolidated financial statements.</p> </div>
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-151000
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2414000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1529398000
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P9Y8M12D
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-1951000
	us-gaap	Goodwill Impaired Change In Estimate Description GoodwillImpairedChangeInEstimateDescription	For example, a sustained, long-term reduction of 3% in operating income for HCP California, HCP Nevada and HCP New Mexico could reduce their estimated fair values by up to 2.4%, 2.9% and 2.7%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California, HCP Nevada and HCP New Mexico by up to 5.1%, 6.0% and 5.7%, respectively.
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.38
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	Segment
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216695033	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.43
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.43
	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	7138000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1804000	shares
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>9. Contingencies</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"> <b><i>Inquiries by the Federal Government and Certain Related Civil Proceedings</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <u>Vainer Private Civil Suit</u>: In December 2008, the Company received a subpoena for documents from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company has been in contact with the U.S. Attorney’s Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC since November 2008 relating to this matter, and has been advised that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the <i>qui tam</i> provisions of the federal False Claims Act. On April 1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney’s Office filed a notice of declination stating that the federal government would not be intervening and not pursuing the relators’ allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">  </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <u>2010 U.S. Attorney Physician Relationship Investigation</u>: As previously disclosed, the U.S. Attorney’s Office for the District of Colorado and the OIG have been investigating, among other things, the Company’s financial relationships with physicians and joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute and the False Claims Act. This investigation has been described in the Company’s prior Reports on Forms 10-K and 10-Q and referred to as the 2010 U.S. Attorney Physician Relationship Investigation. This investigation overlapped substantially with the investigation described below under the caption 2011 U.S. Attorney Physician Relationship Investigation. The Company disclosed earlier this year it had reached an agreement in principle with the government to resolve these matters.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> As described more fully in the Company’s current report on Form 8-K filed on October 23, 2014, the Company entered into a final settlement agreement on October 22, 2014 (the Settlement Agreement) with the United States of America, acting through the United States Department of Justice and on behalf of the OIG, the Defense Health Agency on behalf of TRICARE, through its General Counsel (collectively, the United States) and relator David Barbetta, to resolve the pending 2010 and 2011 U.S. Attorney Physician Relationship Investigations. In connection with the resolution of these matters, the Company has agreed to pay to the United States $350 million plus accrued interest from the date of the Company’s agreement in principle with the United States, plus a civil forfeiture of $39 million. In addition, the Company has agreed in principle to a settlement of certain state Medicaid claims in the amount of $11.5 million plus interest. Under the Settlement Agreement, among other things, the United States agrees to release the Company from any civil or administrative monetary liability arising from allegations that the Company caused the submission of claims to the federal health care programs that were ineligible for reimbursement due to certain violations of the Anti-Kickback Statute in connection with certain of its dialysis center joint venture arrangements, and the United States and the relator agree to dismissal of the civil action filed by the relator under the <i>qui tam</i> provisions of the federal False Claims Act. The Company also has entered into a five-year corporate integrity agreement (the Corporate Integrity Agreement) with the OIG. The Corporate Integrity Agreement, among other things, (i) requires that the Company maintain certain elements of its compliance programs, (ii) imposes certain expanded compliance-related requirements during the term of the Corporate Integrity Agreement, including the appointment of a compliance monitor, and (iii) contains certain business restrictions related to a subset of the Company’s joint venture arrangements, including the Company’s agreeing to: (1) unwind 11 joint venture transactions that were created through partial divestitures to or partial acquisitions from nephrologists and that cover 26 of the Company’s 2,119 clinics; (2) not enter into certain types of partial divestiture joint venture transactions with nephrologists during the term of the Corporate Integrity Agreement; and (3) certain other restrictions. In the event of a breach of the Corporate Integrity Agreement, the Company could become liable for payment of certain stipulated penalties, or could be excluded from participation in federal health care programs. The costs associated with compliance with the Corporate Integrity Agreement could be substantial and may be greater than we currently anticipate. In 2013, the Company accrued an estimated loss contingency reserve of $397,000 related to this matter. In the third quarter of 2014, the Company accrued an additional $17,000 related to this matter which resulted in an increase in the reserve from $397,000 to $414,000.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <u>2011 U.S. Attorney Physician Relationship Investigation</u>: In August 2011, the Company announced it had learned that the U.S. Attorney’s Office for the District of Colorado would be investigating certain activities of its dialysis business in connection with information being provided to a grand jury. This investigation related to the Company’s relationships with physicians, including its joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute, and overlapped substantially with the 2010 U.S. Attorney Physician Relationship Investigation described above. As described above, both the 2010 and 2011 U.S. Attorney Physician Relationship Investigations have now been resolved. The United States has informed the Company that it has declined to proceed with any criminal charges in connection with this matter.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">  </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <u>2011 U.S. Attorney Medicaid Investigation</u>: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company’s understanding that this inquiry is civil in nature. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company has cooperated with the government and produced the requested documents. In April 2014, we reached an agreement in principle to resolve this matter. The specific terms of a settlement have not been finalized.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <u>Swoben Private Civil Suit</u>: In April 2013, the Company’s HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the <i>qui tam</i> provisions of the federal False Claims Act and the California False Claims Act, James M. Swoben, as relator, filed a <i>qui tam</i> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a settlement agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal False Claims Act and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services. In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court’s disposition of the appeal is pending.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">  </p> <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> <u>In re DaVita HealthCare Partners Inc. Derivative Litigation</u>: On January 7, 2014, the U.S. District Court for the District of Colorado consolidated the two previously disclosed shareholder derivative lawsuits: the Haverhill Retirement System action filed on May 17, 2013 and the Clark Shareholder action filed on August 7, 2012. The court appointed Haverhill lead plaintiff. The complaints filed against the directors of the Company and against the Company, as nominal defendant allege, among other things, that our directors breached fiduciary duties to the Company relating to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations described above, the Vainer qui tam private civil suit described above and the Woodard qui tam private civil suit for which the Company previously announced a settlement in July 2012. The Company has entered into a settlement with the lead plaintiff, subject to court approval. The terms of the settlement, which will be described in a court-approved notice, include enhancements to the Company’s corporate governance practices and provides that the Company will not oppose the derivative plaintiff’s application for an award of fees and expenses, the dollar amount of which is not material to the Company.</p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"> <i>Other</i></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court’s decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and that settlement has been finalized. The amount of the settlement is not material to the Company’s consolidated financial statements. The Company intends to continue to vigorously defend against the remaining claims. Any potential settlement of the remaining claims is not anticipated to be material to the Company’s consolidated financial statements.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.</p> </div>
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	27331000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	212086735	shares
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	163046000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11871000
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	6543880000
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	9467089000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	443507000
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	105143000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8979000
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	515094000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2622000
	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	2435480000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	32665000
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	16075000
	us-gaap	Profit Loss ProfitLoss	612942000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25198000
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	6273660000
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	218117000
	us-gaap	Operating Income Loss OperatingIncomeLoss	1363056000
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	757949000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	506115000
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	46587984000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	838000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	955308000
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	12069000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2145000
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-7177000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	515094000
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	1851000
	us-gaap	Goodwill Other Changes GoodwillOtherChanges	12881000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	122154000
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	32483000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	443507000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	515094000
	us-gaap	Net Income Loss NetIncomeLoss	515094000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-16610000
	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	218117000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	517000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	18692000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	612942000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	603963000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2167000
	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	45527000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	437682000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1582000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	147570000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1321000
	us-gaap	Share Based Compensation ShareBasedCompensation	44323000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	916456000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	72932000
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	27781000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	32665000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	72283000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-23770000
	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	17000000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9680000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	580786000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	342366000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-831185000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-9759000
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	3620000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	437682000
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	146399000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-150307000
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	312345000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-119009000
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3777000
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	3620000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14524000
	us-gaap	Costs And Expenses CostsAndExpenses	8104033000
	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	270220000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	340000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	905519000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2332000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	97848000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	97848000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	207000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	46619292000
	dva	Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss	2414000
	dva	Debt Expense DebtExpense	312345000
	dva	Business Combination Contingent Consideration Acquisitions BusinessCombinationContingentConsiderationAcquisitions	18234000
	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	1000	shares
	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	515094000
	dva	Related Party Ownership Interest In Parent Company RelatedPartyOwnershipInterestInParentCompany	0.50	pure
CY2014Q3	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	2143562000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	437536000
CY2014Q3	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	259716000
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	171832000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	336412000
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	31298000
	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	434000
	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	30604000
	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-6007000
	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	214280000	shares
	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	515094000
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	8415000
	dva	Agreement Period AgreementPeriod	P5Y
	dva	Accounts Receivable Months Outstanding AccountsReceivableMonthsOutstanding	P4M
	dva	Patient Care Costs PatientCareCosts	6752844000
	dva	Business Combination Contingent Consideration Acquisitions Earnouts Payments BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments	2715000
	dva	Increase Decrease In Prior Year Estimates Of Health Care Costs Payable IncreaseDecreaseInPriorYearEstimatesOfHealthCareCostsPayable	6442000
	dva	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest	38083000
	dva	Debt Refinancing Charge DebtRefinancingCharge	97548000
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-7563000
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	173181000
	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	437335000
	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	88323000
	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition	P1Y1M6D
	dva	Payments To Acquire Intangible Assets And Equity Method Investments PaymentsToAcquireIntangibleAssetsAndEquityMethodInvestments	50000
	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	409893000
	dva	Litigation Settlement Amount Before Accrued Interest LitigationSettlementAmountBeforeAccruedInterest	350000000
	dva	Litigation Settlement Civil Forfeiture LitigationSettlementCivilForfeiture	39000000
	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	514943000
CY2014Q2	us-gaap	Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet	2972000
CY2013	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	2728000
CY2013	us-gaap	Goodwill Other Changes GoodwillOtherChanges	8315000
CY2013	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	271267000
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.64
CY2013Q3	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2013Q3	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	21000
CY2013Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2314000	shares
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.64
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	214902860	shares
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.65
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.65
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4908000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	210394560	shares
CY2013Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2741000
CY2013Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2126699000
CY2013Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2999586000
CY2013Q3	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	141131000
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-880000
CY2013Q3	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	136887000
CY2013Q3	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	747264000
CY2013Q3	us-gaap	Profit Loss ProfitLoss	169836000
CY2013Q3	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	2052222000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	377074000
CY2013Q3	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	200100000
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	135748000
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	270766000
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2113000
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-7733000
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	136887000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	136628000
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	648000
CY2013Q3	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	259000
CY2013Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	136628000
CY2014Q3	us-gaap	Profit Loss ProfitLoss	219784000
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	305138000
CY2013Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	33208000
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	33208000
CY2013Q3	dva	Debt Expense DebtExpense	108421000
CY2013Q3	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	5000	shares
CY2013Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	136887000
CY2013Q3	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	212584000	shares
CY2013Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	136887000
CY2013Q3	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	18657000
CY2013Q3	dva	Patient Care Costs PatientCareCosts	2095334000
CY2013Q3	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	108421000
CY2014Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-12290000
CY2014Q3	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	184122000
CY2014Q3	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	848546000
CY2013Q3	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	136649000
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
CY2014Q3	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2014Q3	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-2278000
CY2014Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0452	pure
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2425000	shares
CY2013Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	9223000
CY2013Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	169836000
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	168956000
CY2013Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	132765000
CY2013Q3	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	97000000
CY2013Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1498000
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100930000
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-3464000
CY2013Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	132765000
CY2013Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	108421000
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	2622512000
CY2013Q3	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	74477000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.85
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	217236493	shares
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.87
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1422000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	212617238	shares
CY2014Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-13838000
CY2014Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2242533000
CY2014Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	3251824000
CY2014Q3	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	164914000
CY2014Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	184122000
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	184122000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	184122000
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-392000
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1246000
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	537000
CY2014Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	5225000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	219784000
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	207494000
CY2014Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	149196000
CY2014Q3	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	17000000
CY2014Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3961000
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	116628000
CY2014Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-1403000
CY2014Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	149196000
CY2014Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	99878000
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	2814288000
CY2014Q3	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	98971000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	322822000
CY2014Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	35662000
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	35662000
CY2014Q3	dva	Debt Expense DebtExpense	99878000
CY2014Q3	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	1000	shares
CY2014Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	184122000
CY2014Q3	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	214810000	shares
CY2014Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	184122000
CY2014Q3	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	3527000
CY2014Q3	dva	Patient Care Costs PatientCareCosts	2326534000
CY2014Q3	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	99878000
CY2014Q3	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	181844000

Files In Submission

Name	View Source	Status
0001193125-14-401322-index-headers.html	Edgar Link	pending
0001193125-14-401322-index.html	Edgar Link	pending
0001193125-14-401322.txt	Edgar Link	pending
0001193125-14-401322-xbrl.zip	Edgar Link	pending
d793879d10q.htm	Edgar Link	pending
d793879dex101.htm	Edgar Link	pending
d793879dex102.htm	Edgar Link	pending
d793879dex103.htm	Edgar Link	pending
d793879dex104.htm	Edgar Link	pending
d793879dex105.htm	Edgar Link	pending
d793879dex121.htm	Edgar Link	pending
d793879dex311.htm	Edgar Link	pending
d793879dex312.htm	Edgar Link	pending
d793879dex321.htm	Edgar Link	pending
d793879dex322.htm	Edgar Link	pending
dva-20140930.xml	Edgar Link	completed
dva-20140930.xsd	Edgar Link	pending
dva-20140930_cal.xml	Edgar Link	unprocessable
dva-20140930_def.xml	Edgar Link	unprocessable
dva-20140930_lab.xml	Edgar Link	unprocessable
dva-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2014 Q4 Form 10-Q Financial Statement

#000119312514401322 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2014 Q4 Form 10-Q Financial Statement

#000119312514401322 Filed on November 06, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva